Skip to main content

Table 1 Antimicrobial susceptibility of Neisseria gonorrhoeae isolates (n = 156) from Bishkek, Kyrgyzstan, 2012 (n = 84) and 2017 (n = 72)

From: Antimicrobial resistance and molecular epidemiological typing of Neisseria gonorrhoeae isolates from Kyrgyzstan in Central Asia, 2012 and 2017

  

2012 (n = 84)

2017 (n = 72)

Total (n = 156)

  

S

Ia

Rb

S

Ia

Rb

S

Ia

Rb

CRO

N

84

NA

0

72

NA

0

156

NA

0

 

%

(95% CI)

100

(95.7–100)

NA

0

(0–4.3)

100

(95.0–100)

NA

0

(0–5.0)

100

(97.7–100)

NA

0

(0–2.3)

CFM

N

84

NA

0

71

NA

1

155

NA

1

 

%

(95% CI)

100

(95.7–100)

NA

0

(0–4.3)

98.6

(92.5–100)

NA

1.4

(0–7.5)

99.4

(96.6–100)

NA

0.6

(0.01–3.5)

SPC

N

84

NA

0

72

NA

0

156

NA

0

 

%

(95% CI)

100

(95.7–100)

NA

0

(0–4.3)

100

(95.0–100)

NA

0

(0–5.0)

100

(97.7–100)

NA

0

(0–2.3)

AZM

N

83

NA

1

72

NA

0

155

NA

1

 

%

(95% CI)

98.8

(93.5–100)

NA

1.2

(0.03–6.5)

100

(95–100)

NA

0

(0–5.0)

99.4

(96.6–100)

NA

0.6

(0.01–3.5)

CIP

N

12

0

72

5

1

66

17

1

138

 

%

(95% CI)

14.3

(7.6–23.6)

0

(0–4.3)

85.7

(76.4–92.4)

6.9

(2.3–15.4)

1.4

(0.04–7.5)

91.7

(82.8–96.9)

10.9

(6.5–16.9)

0.6

(0.01–3.5)

88.5

(82.4–93.1)

PEN

N

6

52

26

3

34

35

9

86

61

 

%

(95% CI)

7.1

(2.6–14.9)

61.9

(50.7–72.3)

31.0

(21.4–42.0)

4.2

(0.9–11.7)

47.2

(35.3–59.3)

48.6

(36.6–60.7)

5.8

(2.7–10.7)

55.1

(46.9–63.1)

39.1

(31.4–47.2)

TET

N

ND

ND

ND

18

13

41

Data available only in 2017

 

%

(95% CI)

ND

ND

ND

25

(15.5–36.6)

18.1

(10.0–29.0)

56.9

(44.7–68.5)

KAN

N

47

33

4

ND

ND

ND

Data available only in 2012

 

%

(95% CI)

56

(44.7–66.8)

39.3

(28.8–50.6)

4.7

(1.3–11.7)

ND

ND

ND

GEN

N

83

1

0

69

2

1

152

3

1

 

%

(95% CI)

98.8

(93.5–199)

1.2

(0.03–6.5)

0

(0–4.3)

95.8

(88.3–99.1)

2.8

(0.4–9.7)

1.4

(0.04–7.5)

97.4

(93.5–99.3)

2

(0.4–5.6)

0.6

(0.01–3.5)

  

n = 75

n = 72

n = 147

  

Negative/Positive

PPNG

N

60

15

55

17

115

32

 

% (95% CI)

80 (69.2–88.4)

20 (11.7–30.8)

76.4 (64.9–85.6)

23.6 (14.4–35.1)

78.2 (70.7–84.6)

21.8 (15.4–29.4)

  1. S, susceptible; I, susceptible, increased exposure; R, resistant; CRO, ceftriaxone; CFM, cefixime; AZM, azithromycin; SPC, spectinomycin; CIP, ciprofloxacin; PEN, benzylpenicillin; TET, tetracycline; KAN, kanamycin; PPNG, penicillinase-producing Neisseria gonorrhoeae; n, number of isolates; CI, confidence interval; NA, not applicable; ND, Not determined
  2. aA microorganism is categorised as “Susceptible, Increased exposure” when there is a high likelihood of therapeutic success because exposure to the agent is increased by adjusting the dosing regimen or by its concentration at the site of infection (www.eucast.org/newsiandr/)
  3. bThe breakpoints (susceptible/resistant) from the EUCAST [48] were as follows: ceftriaxone and cefixime (MIC≤0.125/> 0.125 mg/L), azithromycin (MIC≤1/> 1 mg/L), spectinomycin (MIC≤64/> 64 mg/L), ciprofloxacin (MIC≤0.032/> 0.064 mg/L), benzylpenicillin (MIC≤0.064/> 1.0 mg/L), and tetracycline (MIC≤0.5/> 1.0 mg/L). Previously published breakpoints were used for gentamicin (MIC≤4/> 16 mg/L [49]) and kanamycin (MIC≤4/≥16 mg/L) [50, 51]